BTIG Research Begins Coverage on VYNE Therapeutics (NASDAQ:VYNE)

Analysts at BTIG Research started coverage on shares of VYNE Therapeutics (NASDAQ:VYNE) in a report released on Monday,Briefing.com Automated Import reports. The firm set a “buy” rating and a $8.00 price target on the stock. BTIG Research’s price objective indicates a potential upside of 196.30% from the stock’s current price.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $5.75 target price on shares of VYNE Therapeutics in a report on Friday, November 8th.

VYNE Therapeutics Stock Down 4.9 %

NASDAQ VYNE opened at $2.70 on Monday. The company has a 50-day moving average price of $2.27 and a 200-day moving average price of $2.18. VYNE Therapeutics has a 52 week low of $1.57 and a 52 week high of $4.30. The firm has a market capitalization of $39.83 million, a P/E ratio of -3.14 and a beta of 1.32.

Hedge Funds Weigh In On VYNE Therapeutics

An institutional investor recently bought a new position in VYNE Therapeutics stock. Virtu Financial LLC acquired a new stake in shares of VYNE Therapeutics Inc. (NASDAQ:VYNE) during the first quarter, according to its most recent disclosure with the SEC. The fund acquired 16,199 shares of the company’s stock, valued at approximately $50,000. Virtu Financial LLC owned approximately 0.11% of VYNE Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 83.78% of the company’s stock.

VYNE Therapeutics Company Profile

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.